Novartis India Acquires Minipress Trademarks for Rs 1,250,00,10,000; Know More

On Monday, Indian equity benchmark indices traded lower, with the benchmark Nifty 50 index falling 123.50 points, or 0.52 per cent, to 23,774.20. Amid the market movement, Novartis India Limited share price rose 0.50 per cent to Rs 1,655 after the company approved the acquisition of the Minipress and Minipres trademarks registered in India, along with certain related intellectual property rights, for a total aggregate consideration of Rs 1,250,00,10,000.

Novartis India informed that its Board of Directors approved the transaction at a meeting held on September 7, 2026. Following the approval, the company executed an asset purchase agreement and trademark assignment deeds with Pfizer Inc. USA and Pfizer Products Inc. USA on the same day. The signing and closing of the transaction are to take place simultaneously.

Novartis India to Pay Rs 1,250,00,10,000 for the Transaction

Under the transaction, Pfizer Inc. USA and Pfizer Products Inc. USA will assign the Minipress and Minipres trademarks registered in India, along with certain related intellectual property rights, to Novartis India Limited. The total aggregate consideration payable by Novartis India to the two Pfizer entities stands at Rs 1,250,00,10,000, as disclosed in the company's regulatory filing.

The acquisition gives Novartis India ownership of the specified trademarks and associated intellectual property rights in the Indian market.

Minipress XL Recorded Revenue of Rs 228.6 Crore

According to IQVIA MAT July 2026 data disclosed by the company, Minipress XL recorded revenue of Rs 228.6 crore. The brand has grown at a compound annual growth rate of 6.3 per cent over the past four years.

During the same four-year period, the category in which the product operates recorded a CAGR of 9 per cent. The Rs 228.6 crore revenue figure provides context to Novartis India's decision to commit Rs 1,250,00,10,000 towards acquiring the trademarks and related intellectual property rights.

What Is Minipress XL?

Minipress XL contains prazosin and is primarily indicated in India for the treatment of hypertension, or high blood pressure, as well as for managing urinary symptoms associated with benign prostatic hyperplasia, or BPH. The transaction therefore gives Novartis India control over the Minipress and Minipres trademarks and certain related intellectual property rights for a product that already has an established revenue base in India.

With Minipress XL recording Rs 228.6 crore in revenue as per MAT July 2026 data, the acquisition for Rs 1,250,00,10,000 represents a sizeable transaction for the company.
Also Read - PVR Inox share price falls 8%: What triggered the sharp sell-off in the multiplex stock?

About the Company:

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. It imports various medicines to India from different sources across the globe 

Disclaimer: The article is for informational purposes only and not investment advice.